Information de reference pour ce titreAccession Number: | 00054725-200906000-00023.
|
Author: | Ng, Siew C. MRCP 1; Kamm, Michael A. MD 2,*
|
Institution: | (1) St Mark's Hospital, London, UK (2) St Vincent's Hospital & Melbourne University, Melbourne, Australia and Imperial College, London, UK (*)St Vincent's Hospital, University Department of Medicine, Victoria Parade, Fitzroy, Melbourne 3065, Australia
|
Title: | |
Source: | Inflammatory Bowel Diseases. 15(6):935-950, June 2009.
|
Abstract: | Induction and maintenance of remission, mucosal healing, the avoidance of surgical intervention, and decreasing the likelihood of cancer developing are the primary therapeutic goals in ulcerative colitis (UC). For the traditional therapies, 5-aminosalicylic acid (including mesalamine), corticosteroids, and thiopurines (azathioprine and mercaptopurine), there are major changes evolving in terms of formulation, patterns of use, and appreciation of long-term benefits and toxicities. The calcineurin inhibitors cyclosporin and tacrolimus, and infliximab, have recently defined, well-established roles. Preliminary supportive evidence is emerging in relation to novel antiinflammatory molecules such as curcumin, manipulation of the bacterial flora, enhancement of the mucosal barrier, and direct epithelial restoration. For patients in whom the disease is resistant to standard simple therapies, strategies are required to integrate these developing and new therapies into clinical practice. This review aims to highlight the evidence supporting new patterns of use of existing therapies and new therapies, and to devise therapeutic pathways that incorporate these new treatments. We propose how treatment might be optimized to improve the outcome in patients with mild-to-moderately active UC, chronic active UC, resistant proctitis, and fulminant UC.
(C) Crohn's & Colitis Foundation of America, Inc.
|
Author Keywords: | ulcerative colitis; therapeutic goals; management.
|
References: | 1. Travis SPL, Stange EF, Lemann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. J Crohn's Colitis. 2008; 2: 24-62.
2. Stange EF, Travis SP. The European Consensus on ulcerative colitis: new horizons? Gut. 2008; 57: 1029-1031.
3. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 1997; 92: 204-211.
4. Stange EF, Travis SPL, Vermeire S, et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohn's Colitis. 2008; 2: 1-23.
5. Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; CD000543.
6. Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53(suppl 5): V1-16.
7. Sutherland L, Roth D, Beck P, et al. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2002; CD000544.
8. Myers B, Evans DN, Rhodes J, et al. Metabolism and urinary excretion of 5-amino salicylic acid in healthy volunteers when given intravenously or released for absorption at different sites in the gastrointestinal tract. Gut. 1987; 28: 196-200.
9. Lichtenstein GR, Kamm MA. Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis - methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. Aliment Pharmacol Ther. 2008; 28: 663-673.
10. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008; 27: 1094-1102.
11. Picco MF, Krishna M, Cangemi JR, et al. Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis. Inflamm Bowel Dis. 2006; 12: 537-542.
12. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut. 1997; 40: 775-781.
13. Marshall JK, Irvine EJ. Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol. 2000; 95: 1628-1636.
14. Regueiro M, Loftus EV Jr, Steinhart AH, et al. Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis. 2006; 12: 972-978.
15. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther. 1997; 11: 1053-1057.
16. Cohen RD, Woseth DM, Thisted RA, et al. A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol. 2000; 95: 1263-1276.
17. Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment Pharmacol Ther. 2007; 26: 21-29.
18. Lee FI, Jewell DP, Mani V, et al. A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut. 1996; 38: 229-233.
19. Regueiro M, Loftus EV Jr, Steinhart AH, et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis. 2006; 12: 979-994.
20. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997; 92: 1867-1871.
21. Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3 mg) versus 5-aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996; 8: 549-553.
22. Malchow H, Gertz B. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Aliment Pharmacol Ther. 2002; 16: 415-423.
23. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut. 2005; 54: 960-965.
24. Campieri M, Gionchetti P, Belluzzi A, et al. Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. Gut. 1991; 32: 929-931.
25. Hanauer SB. Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. Inflamm Bowel Dis. 1998; 4: 79-83.
26. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004; 99: 1371-1385.
27. Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. Am J Gastroenterol. 1993; 88: 1188-1197.
28. Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut. 1998; 42: 761-763.
29. Travis SP. Review article: induction therapy for patients with active ulcerative colitis. Aliment Pharmacol Ther. 2006; 24(suppl 1): 10-16.
30. Lichtenstein GR, Sbreu MT, Cohen R, et al. [American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease.]. Rev Gastroenterol Mex. 2006; 71: 351-401.
31. Kamm MA, Lichtenstein G, Sandborn WJ. Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. Inflamm Bowel Dis. 2008 (in press).
32. Campieri M, Adamo S, Valpiani D, et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther. 2003; 17: 1471-1480.
33. Kamm MA, Lichtenstein GR, Sandborn WJ, et al. Randomised trial of once- or twice-daily MMXTM mesalazine for maintenance of remission in ulcerative colitis. Gut. 2008; 57: 893-902.
34. Dignass A, Veerman H. Once-versus twice-daily mesalazine (Pentasa) granules for the maintenance of remission in ulcerative colitis: results from a multuinational randomised controlled trial. Gut. 2008 (in press).
35. Kruis W, Gorelov A, Kiudelis G. Once daily dosing of 3g mesalamine (Salofalk granules) is therapeutic equivalent to a three-times daily dosing of 1g mesalamine for the treatment of active ulcerative colitis. Gastroenterolgy. 2007; 132: A-130. Abstract 898.
36. Hanauer S, Good LI, Goodman MW, et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol. 2000; 95: 1749-1754.
37. Mantzaris GJ, Hatzis A, Petraki K, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum. 1994; 37: 58-62.
38. Marteau P, Crand J, Foucault M, et al. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study. Gut. 1998; 42: 195-199.
39. D'Albasio G, Trallori G, Ghetti A, et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum. 1990; 33: 394-397.
40. D'Albasio G, Pacini F, Camarri E, et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol. 1997; 92: 1143-1147.
41. Piodi LP, Ulivieri FM, Cermesoni L, et al. Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. Scand J Gastroenterol. 2004; 39: 154-157.
42. Orchard T, Probert CS, Keshav S. Review article: maintenance therapy in patients with ulcerative colitis. Aliment Pharmacol Ther. 2006; 24(suppl 1): 17-22.
43. Kale-Pradhan PB, Pradhan RS, Wilhelm SM. Multi-matrix system mesalamine: to use or not to use. Ann Pharmacother. 2008; 42: 265-269.
44. McCormack PL, Robinson DM, Perry CM. Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis. Drugs. 2007; 67: 2635-2642.
45. Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol. 2003; 1: 36-43.
46. Sninsky CA, Cort DH, Shanahan F, et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med. 1991; 115: 350-355.
47. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987; 317: 1625-1629.
48. Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol. 2005; 100: 2478-2485.
49. Sandborn WJ, Regula J, Feagan B, et al. Efficacy and safety of delayed-release oral mesalamine at 4.8g/D (800 mg tablet) in the treatment of moderately active ulcerative colitis: results of the ASCEND III Study. Gastroenterology. 2008; 134: A-99. Abstract 702.
50. Levine DS, Riff DS, Pruitt R, et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol. 2002; 97: 1398-1407.
51. Meyers S, Sachar DB, Present DH, et al. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology. 1987; 93: 1255-1262.
52. Sandborn WJ, Kamm MA, Lichtenstein GR, et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2007; 26: 205-215.
53. D'Haens G, Hommes D, Engels L, et al. Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. Aliment Pharmacol Ther. 2006; 24: 1087-1097.
54. Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007; 132: 66-75.
55. Lichtenstein GR, Kamm MA, Boddu P, et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2007; 5: 95-102.
56. Safdi AV, Cohen RD. Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates. Aliment Pharmacol Ther. 2007; 26: 1179-1186.
57. Irvine EJ, Magowan S, Pasquale M. Rapid clinical remission is significant for the well-being of ulcerative colitis patients treated with delayed-release mesalamine. Am J Gastroenterol. 2008; Abstract 942.
58. Sandborn WJ, Katz S, Ramsey D. Rapid symptom resolution with delayed-release mesalamine in mildly and moderately active ulcerative colitis. Am J Gastroenterol. 2008; Abstract 943.
59. Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med. 1993; 118: 540-549.
60. Schreiber S, Hamling J, Zehnter E, et al. Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. Gut. 1997; 40: 761-766.
61. Hussain FN, Ajjan RA, Riley SA. Dose loading with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters. Br J Clin Pharmacol. 2000; 49: 323-330.
62. Farup PG, Hinterleitner TA, Lukas M, et al. Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. Inflamm Bowel Dis. 2001; 7: 237-242.
63. Marteau P, Florent C. Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis: French Pentasa Study Group. Am J Gastroenterol. 2000; 95: 166-170.
64. Bianchi PG, Cassinotti A, Ferrara E, et al. Review article: the management of steroid dependency in ulcerative colitis. Aliment Pharmacol Ther. 2007; 26: 779-794.
65. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002; 50: 485-489.
66. Lobo AJ, Foster PN, Burke DA, et al. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum. 1990; 33: 374-377.
67. Steinhart AH, Baker JP, Brzezinski A, et al. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol. 1990; 12: 271-275.
68. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J. 1974; 4: 627-630.
69. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004; 99: 1122-1128.
70. Rosenberg JL, Wall AJ, Levin B, et al. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology. 1975; 69: 96-99.
71. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed). 1982; 284: 1291-1292.
72. Ardizzone S, Maconi G, Russo A, et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006; 55: 47-53.
73. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992; 305: 20-22.
74. Leung Y, Panaccione R, Hemmelgarn B, et al. Exposing the weaknesses: a systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci. 2007; 53: 1455-1461.
75. Timmer A, McDonald JW, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007; CD000478.
76. Rayner CK, Hart AL, Hayward CM, et al. Azathioprine dose escalation in inflammatory bowel disease. Aliment Pharmacol Ther. 2004; 20: 65-71.
77. Sparrow MP, Hande SA, Friedman S, et al. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol. 2007; 5: 209-214.
78. Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2008 (in press).
79. Benson A, Barrett T, Sparberg M, et al. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis. 2008; 14: 7-12.
80. Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 129-134.
81. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature. 1991; 352: 803-807.
82. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs. 1993; 46: 746-794.
83. Fellermann K, Tanko Z, Herrlinger KR, et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis. 2002; 8: 317-324.
84. Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther. 2003; 17: 1273-1281.
85. Ziring DA, Mow W, Ament ME. Oral tacrolimus in children with ulcerative colitis: 1 5 year experience. Gastroenterology. 2006; Abstract, 1211.
86. Yamamoto S, Nakase H, Inoue S, et al. Long-term outcome of treatment with tacrolimus therapy in patients with ulcerative colitis. Gastroenterology. 2008; Abstract W1223.
87. Ogata H, Matsui T, Nakamura M, et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut. 2006; 55: 1255-1262.
88. Herrlinger KR, Fellermann K, Stange EF. Tacrolimus-finally.! Gut. 2006; 55: 1224-1225.
89. Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci. 2006; 51: 1833-1840.
90. Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2007; 6: 479-485.
91. Ullman TA. Tacrolimus for active ulcerative colitis? Yes! (Even though Cochrane says "no"). Gastroenterology. 2007; 132: 1192-1194.
92. Kozarek RA, Patterson DJ, Gelfand MD, et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med. 1989; 110: 353-356.
93. Cummings JR, Herrlinger KR, Travis SP, et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther. 2005; 21: 385-389.
94. Wahed M, Louis-Auguste JR, Baxter LM. Efficacy of methotrexate in ulcerative colitis. Gastroenterology. 2008; Abstract 399.
95. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology. 1996; 110: 1416-1421.
96. Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol. 2008; 23: 954-958.
97. Chande N, Macdonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007; CD006618.
98. Ferlitsch A, Teml A, Reinisch W, et al. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol. 2007; 102: 2495-2503.
99. Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology. 2003; 125: 298-303.
100. Gilissen LP, Derijks LJ, Driessen A, et al. Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects? Dig Liver Dis. 2007; 39: 156-159.
101. Qasim A, McDonald S, Sebastian S, et al. Efficacy and safety of 6-thioguanine in the management of inflammatory bowel disease. Scand J Gastroenterol. 2007; 42: 194-199.
102. de Boer NK, Zondervan PE, Gilissen LP, et al. Absence of nodular regenerative hyperplasia after low-dose 6-thioguanine maintenance therapy in inflammatory bowel disease patients. Dig Liver Dis. 2008; 40: 108-113.
103. de Boer NK, van Bodegraven AA, Jharap B, et al. Drug insight: pharmacology and toxicity of thiopurine therapy in patients with IBD. Nat Clin Pract Gastroenterol Hepatol. 2007; 4: 686-694.
104. Vernier-Massouille G, Cosnes J, Lemann M, et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007; 56: 1404-1409.
105. Kashiwagi N, Sugimura K, Koiwai H, et al. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci. 2002; 47: 1334-1341.
106. Abreu MT, Plevy S, Sands BE, et al. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J Clin Gastroenterol. 2007; 41: 874-888.
107. Pineda AA. Developments in the apheresis procedure for the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12(suppl 1): S10-S14.
108. Domenech E, Hinojosa J, Esteve-Comas M, et al. Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment Pharmacol Ther. 2004; 20: 1347-1352.
109. Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004; 10: 251-257.
110. Kanke K, Nakano M, Hiraishi H, et al. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004; 36: 811-817.
111. Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004; 70: 36-44.
112. Sandborn WJ. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis. 2006; 12(suppl 1): S15-S21.
113. Ljung T, Thomsen OO, Vatn M, et al. Granulocyte, monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007; 42: 221-227.
114. Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol. 2005; 100: 1362-1369.
115. Sands BE, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008; 135: 400-409.
116. Sands BE, Kaplan GG. The role of TNFalpha in ulcerative colitis. J Clin Pharmacol. 2007; 47: 930-941.
117. Panaccione R, Fedorak RN, Aumais G, et al. Review and clinical perspectives for the use of infliximab in ulcerative colitis. Can J Gastroenterol. 2008; 22: 261-272.
118. Diez M, Sanchez E, Garcia LS, et al. [Infliximab therapy in ulcerative colitis: initial experience in two referral centers.]. Gastroenterol Hepatol. 2007; 30: 449-453.
119. Probert CS, Hearing SD, Schreiber S, et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut. 2003; 52: 998-1002.
120. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
121. D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006; 8: 506-512.
122. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2006; 3: CD005112.
123. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005; 100: 1539-1546.
124. Makharia GK, Sood A, Midha V. A randomised, double blind, placebo-controlled trial of a probiotic preparation, VSL#3, for the treatment of mild to moderate active ulcerative colitis. Gastroenterology. 2008; Abstract 701.
125. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003; 15: 697-698.
126. Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007; CD005573.
127. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004; 53: 1617-1623.
128. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999; 354: 635-639.
129. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999; 13: 1103-1108.
130. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005; 50: 2191-2193.
131. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006; 4: 1502-1506.
132. Gionchetti P, Rizzello F, Venturi A, et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998; 41: 93-97.
133. Kam L, Cohen H, Dooley C, et al. A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults. Am J Gastroenterol. 1996; 91: 1338-1342.
134. Regueiro MD. Diagnosis and treatment of ulcerative proctitis. J Clin Gastroenterol. 2004; 38: 733-740.
135. Lennard-Jones JE, Baron JH, Connell AM, et al. A double blind controlled trial of prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Gut. 1962; 3: 207-210.
136. Connell AM, Lennard-Jones JE, Misiewicz JJ, et al. Comparison of acetarsol and prednisolone-21-phosphate suppositories in the treatment of idiopathic proctitis. Lancet. 1965; 1: 238.
137. Lucidarme D, Marteau P, Foucault M, et al. Efficacy and tolerance of mesalazine suppositories vs. hydrocortisone foam in proctitis. Aliment Pharmacol Ther. 1997; 11: 335-340.
138. Lakatos PL, Lakatos L. Ulcerative proctitis: a review of pharmacotherapy and management. Expert Opin Pharmacother. 2008; 9: 741-749.
139. Pinto A, Fidalgo P, Cravo M, et al. Short chain fatty acids are effective in short-term treatment of chronic radiation proctitis: randomized, double-blind, controlled trial. Dis Colon Rectum. 1999; 42: 788-795.
140. Forbes A, Britton TC, House IM, et al. Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther. 1989; 3: 553-556.
141. Ranzi T, Campanini MC, Velio P, et al. Treatment of chronic proctosigmoiditis with cyclosporin enemas. Lancet. 1989; 2: 97.
142. Brynskov J, Freund L, Thomsen OO, et al. Treatment of refractory ulcerative colitis with cyclosporin enemas. Lancet. 1989; 1: 721-722.
143. Sinha A, Nightingale J, West KP, et al. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med. 2003; 349: 350-357.
144. Gionchetti P, Rizzello F, Morselli C, et al. Review article: problematic proctitis and distal colitis. Aliment Pharmacol Ther. 2004; 20(suppl 4): 93-96.
145. Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol. 2007; 5: 103-110.
146. Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994; 330: 1841-1845.
147. D'Haens G, Lemmens L, Geboes K, et al. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology. 2001; 120: 1323-1329.
148. Van AG, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology. 2003; 125: 1025-1031.
149. Rayner CK, McCormack G, Emmanuel AV, et al. Long-term results of low-dose intravenous ciclosporin for acute severe ulcerative colitis. Aliment Pharmacol Ther. 2003; 18: 303-308.
150. Campbell S, Travis S, Jewell D. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol. 2005; 17: 79-84.
151. Actis GC, Fadda M, David E, et al. Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study. BMC Gastroenterol. 2007; 7: 13.
152. Moskovitz DN, Van AG, Maenhout B, et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol. 2006; 4: 760-765.
153. Shah SB, Parekh NK, Hanauer SB, et al. Intravenous cyclosporine in severe steroid-refractory ulcerative colitis: long term follow-up. Gastroenterology. 2008; Abstract, 1041.
154. Cacheux W, Seksik P, Lemann M, et al. Predictive factors of response to cyclosporine in steroid-refractory ulcerative colitis. Am J Gastroenterol. 2008; 103: 637-642.
155. Arts J, D'Haens G, Zeegers M, et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis. 2004; 10: 73-78.
156. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128: 1805-1811.
157. Lees CW, Heys D, Ho GT, et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2007; 26: 411-419.
158. Kohn A, Daperno M, Armuzzi A, et al. Infliximab in severe ulcerative colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther. 2007; 26: 747-756.
159. Jakobovits SL, Jewell DP, Travis SP. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther. 2007; 25: 1055-1060.
160. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007; 13: 123-128.
161. Gisbert JP, Gonzalez-Lama Y, Mate J. Systematic review: Infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther. 2007; 25: 19-37.
162. Maser EA, Deconda D, Lichtiger S, et al. Cyclosporine and infliximab as acute salvage therapies for each other, in severe steroid-refractory ulcerative colitis. Gastroenterology. 2007; 132(suppl 2): S1132 (abstract).
163. Peyrin-Biroulet L, Laclotte C, Roblin X, et al. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol. 2007; 13: 2328-2332.
|
Language: | English.
|
Document Type: | Clinical Reviews.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1078-0998
|
NLM Journal Code: | c2i, 9508162
|
DOI Number: | https://dx.doi.org/10.1002/ibd.2...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|